Sleep disturbances are a common feature for people with Parkinson’s disease, and a device developed to help people with insomnia is now being trialled to see if it can improve their sleep q
In the UK, the drive to integrate digital health services into the NHS continues apace – and the latest initiative will see data from private hospital care integrated into the publicly-fund
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio